AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05891652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified thoracoabdominal nerve block through perichondrial approach
Description: Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
Study NCT04715022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid solution (American Regent Laboratories Inc.)
Description: Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
Study NCT04715022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (saline) will be administered
Study NCT05492968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrin
Description: Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study NCT05492968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study NCT05492968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study NCT04721288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active communication through Reboot application
Description: Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
Study NCT04721288 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Generic communication through Reboot application
Description: Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
Study NCT05380141 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual patient interviews
Description: Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview.
Study NCT04692298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pulses
Description: kidney beans, pinto beans, lentil, black-eyed pea and chickpea
Study NCT05177783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuune health questionnaire
Description: Participants complete the Tuune contraceptive decision aid health questionnaire.
Study NCT05177783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control health questionnaire
Description: Participants complete a standard physician intake health questionnaire.
Study NCT05487820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert
Description: Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
Study NCT05562141 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample before induction, 1h after induction and 24h after the start of procedure
Study NCT05281289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-tape
Description: KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
Study NCT05281289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: 15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
Study NCT05281289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instructions about dealing with calf cramps
Description: instructions about dealing with calf cramps by self low sustained stretch of calf muscle
Study NCT00012662 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Self Management Education
Study NCT06407609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma and boswellia extracts plus low fodmap diet
Description: Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability
Study NCT06407609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Foodmap diet
Description: such as lactose or gluten free diet in the last 6 months
Study NCT05331976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proof Lab Test System
Description: Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
Study NCT04128462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-6105
Description: L-Ornithine Phenylacetate for IV infusion
Study NCT04128462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for IV infusion
Study NCT04128462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
Study NCT04128462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
Study NCT03399838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: IN Dex for pediatric procedural sedation at the emergency department
Study NCT03399838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
Study NCT05492422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Description: Central Executive Training (CET)
Study NCT05492422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: Behavioral Parent Training (BPT)
Study NCT05491863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative physiotherapy plan
Description: Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
Study NCT05491863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative physiotherapy plan
Description: Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
Study NCT05491863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk stability exercise plan
Description: trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
Study NCT05491863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk stability exercise plan
Description: trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
Study NCT05275634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
Study NCT05275634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
Study NCT05275634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 2 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
Study NCT05275634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 4 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
Study NCT05275634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 8 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
Study NCT05275634 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo interferential current
Description: Interferential current intensity will not be raised.
Study NCT04657094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT06538298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Exercise Program with Gamification
Description: A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
Study NCT04964895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)
Study NCT06401837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian based acupressure application
Description: Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
Study NCT02844530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan
Description: The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients
Study NCT02844530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy/ immunotherapy
Study NCT05227664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 at a dose of 45mg/kg via intravenous (IV) infusion on Days 1,8 ,15 and 22of each 28-day cycle until disease progression or unacceptable toxicity
Study NCT05227664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 at a dose of 20mg/kg via intravenous (IV) infusion on Days 1and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05227664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05227664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05710289 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.
Study NCT05584878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curodont repair Self- assembling peptide P11-4
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
Study NCT05584878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ph-chi phosphorylated - nano-chitosan
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
Study NCT05584878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
Study NCT04686292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine flow cytometry
Description: Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
Study NCT05396352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
Study NCT04304261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 12 weeks of Canagliflozin(100mg/day) treatment
Study NCT04304261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 12 weeks of Sitagliptin (100mg/day) treatment
Study NCT05837299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC008
Description: allowing 10% dose error
Study NCT04721964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)
Description: Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
Study NCT06078098 — intervention group
Intervention type: OTHER
Intervention: Clinical Information
Description: We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
Study NCT04679155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Time Restriction
Description: early vs late time of day restriction
Study NCT04679155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating Time Restriction
Description: early vs late time of day restriction
Study NCT04797117 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization.
Study NCT05013515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator.
Study NCT06201468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A SCAPULAR MOBILIZATION
Description: Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.
Study NCT04850378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Drug: Dalteparin 200 units/kg once a day for 4-7 days.
Study NCT04850378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Drug: Apixaban 5 mg twice a day for 4-7 days.
Study NCT04850378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Drug: Apixaban 5 mg twice a day for 4-7 days.
Study NCT06165913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early implant placement(type II)
Description: in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed